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The gene for the transducer of transforming growth factor-beta/bone morphogenetic protein signalling SMAD4, a potential
suppressor of colorectal carcinogenesis, is located at the chromosomal region 18q21. In order to evaluate the clinical
relevance of SMAD4 deletion, gene copy alterations were determined by copy dosage using real-time quantitative PCR in 202
colorectal tumour biopsies from a previous randomised study of adjuvant chemotherapy. Patients with normal SMAD4 diploidy
turned out to have a three-fold higher beneﬁt of 5-ﬂuorouracil-based adjuvant chemotherapy with a border line signiﬁcance
(overall survival: 3.23, P=0.056; disease-free survival: 2.89, P=0.045). These data are consistent with the previous observation
that patients whose cancer had retention of the 18q21 region had a signiﬁcantly higher beneﬁt from 5-ﬂuorouracil-based
therapy. Moreover, these results may provide a reﬁnement at the gene level of the clinical relevance of 18q21 deletion,
thereby suggesting SMAD4 as a predictive marker in colorectal cancer. This data also indicate that integrity of this component
of the transforming growth factor-beta/bone morphogenetic protein signalling pathway may be a critical factor for beneﬁt of
chemotherapy in patients with colorectal cancer.
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Deletion of the chromosomal region 18q21 is the most frequent
cytogenetic alteration observed in colorectal cancer (CRC), suggest-
ing the location of a tumour suppressor locus in this region
(Vogelstein et al, 1988; Mitelman et al, 1997). Searches for such
candidate genes have led to the identiﬁcation of a gene designated
as Deleted in Pancreatic Cancer locus 4 (DPC4) (Hahn et al, 1996;
Thiagalingam et al, 1996). Through its homology with the C.
elegans Small (Sma) proteins (Savage et al, 1996) and with the
Drosophila protein Mothers against dpp (Mad), initially identiﬁed
for its genetic interaction with the gene for the BMP-like peptide
Decapentaplegic (dpp) (Raftery et al, 1995), DPC4 has been renamed
SMAD4 as a merger of Sma and Mad (Derinck et al, 1996).
SMADs form a family of structurally related proteins initially
identiﬁed for their role in embryonic development of Drosophila
(Raftery et al, 1995) and of C. elegans (Savage et al, 1996). Proteins
of the SMAD family can be divided into three distinct subtypes that
correlate with their respective functions in transforming growth
factor beta (TGFb)/bone morphognetic protein (BMP) signalling
(Kretschmar and Massague ￿, 1999; Newfeld et al, 1999), as depicted
in Figure 1: (i) receptor-activated (ra)-SMADs are serine-phospory-
lated upon binding of the cytokine to its cognate receptor. SMAD2
and SMAD3 are speciﬁcally activated by TGFb-like cytokines,
whereas SMAD1, SMAD5 and SMAD8 are exclusively phosphory-
lated by BMPs; (ii) a co-SMAD, SMAD4 heteropolymerises with
activated ra-SMADs. This complex migrates to the nucleus where
it associates with tissue speciﬁc transcription factors. SMAD4 is
the only co-SMAD protein known in mammalians, and therefore
is a common signalling mediator to all TGFb/BMPs; and (iii)
among the immediate target genes for SMAD transcription
complexes are the genes for anti-SMADs. Thus, the anti-SMADs
SMAD6 and SMAD7 prevent activation of ra-SMADs (SMAD1/5/
8 and SMAD2/3, respectively), therefore providing a transient cyto-
kine response through a negative feedback loop. Interestingly,
SMAD2 (Eppert et al, 1996) and SMAD7 (Nakao et al, 1997) genes
have also been assigned to the 18q21 region (Eppert et al, 1996;
Ro ¨ijer et al, 1998), where the SMAD7 gene maps between SMAD2
and SMAD4 genes (Boulay et al, 2001) within four megabases
(Venter et al, 2001). Thus, this region encodes the three classes of
TGFb mediators speciﬁcally required for the signalling of TGFb-like
cytokines, and one, SMAD4, for both TGFb and BMP families.
Genetic evidence for the involvement of TGFb pathway in colon
tumour suppression was given by Markowitz et al (1995), who
observed frequent frameshift mutations within the TGFb-receptor
II coding sequence in CRC, as a result of microsatellite instability.
This observation has been later conﬁrmed in a larger population,
where most tumors with microsatellite instability carry this gene
mutation (Watanabe et al, 2001). On the other hand, TGFb has
been shown to be a potent cell growth inhibitor (Roberts and
Sporn, 1993), and apoptosis inducer on prostatic epithelial cell
lines (Hsing et al, 1996), whereas most squamous carcinoma lines
are refractory to this function (Reiss et al, 1993; Blobe et al, 2000).
Thus, the frequent deletion of the chromosomal region 18q21 in
colorectal tumours together with the physiologic functions of TGFb
strongly suggested a role for SMAD4 in the suppression of color-
ectal carcinogenesis.
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www.bjcancer.comFor these reasons, we wished to study the inﬂuence of the
SMAD4 gene on the clinical outcome of patients with CRC, includ-
ing on beneﬁt of 5FU-based chemotherapy. Indeed, an interaction
between markers and treatment responsiveness or lack thereof has
led to a separation of these factors into prognostic (independent of
treatment) and predictive (interactive with treatment) categories.
To do so, we took advantage of archived colorectal tumour biop-
sies collected in a previous Swiss Association for Clinical Cancer
Research (SAKK) study of 5FU-based perioperative adjuvant ther-
apy (SAKK, 1995). Through a strategy based on quantitative real
time PCR (Boulay et al, 1999, 2001), we performed genetic analyses
of corresponding DNAs by copy dosage of the SMAD4 gene. In
order to study on one hand the prognostic value of genotype,
and on the other hand its predictive effect on the efﬁcacy of
5FU-based therapy among patients with CRC, we undertook multi-
variate statistical analysis of SMAD4 gene copy status on survival.
MATERIALS AND METHODS
Patients
Patients from whom biopsies were isolated, were part of a previous
randomised study of the Swiss Association for Clinical Cancer
Research (SAKK) on beneﬁt of adjuvant chemotherapy (SAKK
study 40/81) (SAKK, 1995). In that study, 533 patients with color-
ectal cancer about to undergo curative resection were randomly
assigned no adjuvant treatment (control group) or an immediate
postoperative infusion with 5FU (500 mg m
72) for 7 days, with
one single dose of mitomycin (10 mg m
72) on day 1. As a result,
patients appeared to signiﬁcantly beneﬁt from this therapy such
that overall survival increased from 55 to 66 months (hazard ratio:
0.74; 95% conﬁdence interval: 0.57–0.97; P=0.026), and disease-
free survival, from 48 to 57 months (hazard ratio: 0.79; 95% conﬁ-
dence interval: 0.62–1.00; P=0.051). The relationship between
genotypes and clinical outcome was assessed in a subset of 202
patients with genetic data for which we also had clinical and survi-
val data. As shown in Table 1, the subgroup for which genetic and
clinical data are available, is closely representative of the patients
treated in the SAKK study 40/81 (SAKK, 1995). Our study
comprises 164 out of the 233 individuals described in our previous
report (Boulay et al, 2001).
Gene copy status scoring
Genomic samples were tested for gene dosage using the TaqMan
1
system on an ABI Prism
1 7700 sequence detector (PE Applied
Biosystems, Foster, USA). All reactions were made in triplicate.
For each individual, the Ct value (calculated by the built-in soft-
ware) obtained for the gene 36B4 (Masiakowski et al, 1982) on
normal tissue was subtracted from that of tumour tissue thus
deﬁning DCt36B4. A similar calculation was made for the SMAD4
gene (DCtSMAD4). Gene copy status is indicated by the DCt value
(DCt36B4–DCtSMAD4) as following. DCt470.45: no deletion;
DCt570.55: hemizygous. Primers: SMAD4, gca gac aga aac tgg
att aaa aca att and gaa tgt gtt tct cct aat ctt caa gct; 36B4: agc
aag tgg gaa ggt gta atc c and cca ttc tat cat caa cgg gta caa. Probes:
SMAD4, tgt tgt ggt ccc tat ggc tgt tta cta tcc a; 36B4: tct cca cag aca
agg cca gga ctc g.
Statistical analysis
Cox proportional hazard modelling was undertaken to assess the
impact of genotype on overall survival and on disease-free survival
after controlling for possible confounding. All analyses were
performed using S Plus. The relationship between genotypes and
survival/disease-free survival was assessed in a subset of 202
patients with genetic data for whom we also had clinical and survi-
val data.
RESULTS
We aimed to test whether the deletion of the SMAD4 gene would
have a signiﬁcant inﬂuence on the outcome of patients with CRC.
Within the individual tumours in this statistical analysis, the
frequency of SMAD4 gene deletion was 67% (135 out of 202). This
deletion frequency was similar to that previously reported (Boulay
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Figure 1 SMADS in the TGFb/BMP signalling pathway: (i) receptor-acti-
vated (ra)-SMADs SMAD2 or SMAD3 are serine-phosporylated upon
TGFb-receptor interaction, whereas SMAD1, SMAD5 or SMAD8 phos-
phorylation is exclusively induced by BMPs; (ii) SMAD4, the common
and unique co-SMAD signalling mediator to all TGFb/BMP cytokines, het-
eropolymerises with activated ra-SMADs and migrates to the nucleus
where it associates with tissue speciﬁc transcription factors (TF); (iii) anti-
SMADs produced upon cytokine induction (SMAD7 for TGFb and
SMAD6 for BMPs) block ra-SMAD serine phosphorylation. This inducible
negative feedback loop provides a transient response to cytokine activation
(see Kretschmar and Massague ￿, 1999). Extracytoplasmic (EC), cytoplasmic
(CP) and nuclear (N) compartments are indicated.
Table 1 Demographics of the SAKK 40/81 patients analysed in this study
Patients in SAKK study 40/81 Patients in this study
n 505 202
Sex (male : female) 277 (55%): 228 (45%) 109 (54%): 93 (46%)
Age (median) 62 62
Nodal status
(positive : negative : unknown) 157 (31%): 315 (62%): 33 (6.5%) 69 (34%): 133 (66%): 0 (0%)
Tumour site
(rectal : colonic) 185 (37%): 320 (63%) 63 (31%): 139 (69%)
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copy dosage and clinical data was investigated in multivariate
statistical analyses that included age, sex, stage, tumour location,
grade, nodal status and chemotherapy as covariates. Hazard ratios
(HR) for death and relapse associated with SMAD4 gene deletion
were close to one (1.22 and 1.16, respectively) with non-signiﬁcant
P values (0.43 and 0.56, respectively, Table 2, top). Thus we
concluded that deletion of SMAD4 gene has no signiﬁcant inﬂu-
ence on the outcome of patients with CRC.
The original clinical study from which tumour samples were
derived had shown the beneﬁt of 5FU-based perioperative adjuvant
chemotherapy in colorectal cancer (SAKK, 1995). Thus, a similar
multivariate statistical analysis was performed to evaluate the dele-
tion of the SMAD4 gene as a potential marker for a predictive
effect on 5FU treatment. Regarding disease-free survival, after
controlling for confounding in the multivariate models, the HR
associated with 5FU treatment among patients with normal diploi-
dy for SMAD4 was 0.32, whereas the HR associated with 5FU
treatment in patients with SMAD4 deletion was 2.89 times as large
(Table 2, bottom). The difference between these two HRs (i.e. the
statistical interaction between gene deletion and the effect of 5FU
chemotherapy) was of borderline statistical signiﬁcance
(P=0.045). A similar result was found for overall survival, the
HR associated with 5FU treatment being 0.25 among patients with
normal SMAD4 genotype and 3.23 times as great among patients
with SMAD4 deletion (Table 2, bottom; Figure 2). As with
disease-free survival, the difference was of borderline statistical
signiﬁcance (P=0.056). This suggests SMAD4 as a predictive
marker for 5FU/mitomycin adjuvant chemotherapy
DISCUSSION
We established that among the patients with colorectal cancer
involved in this study, SMAD4 was deleted in 67% of cases. These
results, obtained by gene copy dosage, are consistent with those
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Table 2 Association of SMAD4 status with patient outcome
Hazard ratio 95% CI P-value
Prognostic effect of SMAD4 gene deletion
Overall survival 1.22 0.75–1.96 0.43
Disease-free survival 1.16 0.74–1.81 0.51
Predictive effect of SMAD4 gene deletion of 5FU adjuvant therapy
Overall survival 3.23 0.97–10.8 0.056
Treated group 2.85 0.98–8.33 0.055
Untreated group 0.87 0.49–1.54 0.64
Disease-free survival 2.89 1.02–8.12 0.045
Treated group 2.31 0.95–5.62 0.066
Untreated group 0.81 0.47–1.40 0.45
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Figure 2 Kaplan–Meier plotting of survival in response to 5FU therapy in patients (n=202) with SMAD4 deletion (top) and with no loss of SMAD4
(bottom). Overall survival (left): HR=3.23, 95% CI=0.97–10.8, P=0.056. Disease-free survival (right): HR=2.89, 95% CI=1.02–8.12, P=0.045.
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et al, 1997) and loss of hetereozygocity (LOH) studies on the 18q21
region (Laurent-Puig et al, 1992; Jen et al, 1994; Martı ￿nez-Lo ￿pez et
al, 1998; Jernwall et al, 1999; Watanabe et al, 2001). However, these
LOH studies are frequently based on microsatellite markers that
span several centiMorgans (cM), and therefore several megabases
(Mb). In contrast to that approach, our strategy allows for a more
reﬁned analysis by targeting an individual gene rather than a wide
chromosomal region that certainly contains a number of important
genes. Thus, it is likely that an analysis at the single gene level will
give a more accurate image of eventual clinical implications of
genetic alterations.
We observed that colorectal cancer patients with normal SMAD4
gene copy status had a three-fold higher beneﬁt of 5FU-based ther-
apy than those with SMAD4 deletion. This result is consistent with
the previous observation by Watanabe et al (2001), that patients
with retention of 18q21 alleles had a beneﬁt of 5FU-based
chemotherapy of the same order as was found in this study. More-
over, reﬁnement of deletion studies from the chromosomal band
level to the gene level may provide a clue to possible mechanisms
through which 18q21 deletion inﬂuences the outcome of patients
with CRC. Therefore, our results reinforce the hypothesis that TGFb
and its signalling components have a role in tumour suppression.
This result also suggests the deﬁnition of SMAD4 as a predictive
marker for beneﬁt of 5FU-based chemotherapy in patients with
colorectal cancer. Finally, these ﬁndings suggests a mode of action
of this cytostatic compound that is SMAD4-dependent. Thus, the
integrity of this component of the TGFb/BMP pathway is not only
required for cytokine signalling, but may also be an important
factor for 5FU-mediated apoptosis. In addition to the requirement
of functional apoptotic pathways such as CD95/Fas (Houghton et
al, 1997), bax (Rampino et al, 1997) and p53 (Vogelstein et al,
2000) for drug sensitivity in colorectal tumour cells, this suggests
that integrity of the TGFb pathway may be an additional condition
for efﬁciency of 5FU treatment. Thus, our results provide an addi-
tional clue to the genetic basis of drug resistance in cancer.
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